QIAGEN Launches Dedicated CRISPR Products for Fast and Simplified Analysis of Gene Editing Experiments
HILDEN, Germany, & GERMANTOWN, Maryland – (COMMERCIAL THREAD) – QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced the launch of QIAprep & CRISPR kit and CRISPR Q-Primer solutions that allow researchers to analyze altered genetic material with unparalleled speed and efficiency to determine how their interventions altered the function of the DNA sequence in question.
The product launch marks QIAGEN’s dedicated solutions specific to the rapidly growing field of CRISPR technology used for genome editing and gene function modification. Short for âshort palindromic repeats grouped evenly spacedâ, CRISPR has a multitude of potential applications, ranging from correcting genetic defects, to treating and preventing the spread of disease and accelerating drug discovery and biomedical research. The new products add to the range of QIAGEN products that could also be used for CRISPR research, such as QIAGEN EndoFree Plasmid Kits and Plasmid Plus Kits.
The QIAprep & CRISPR Kit and new CRISPR Q-Primer solutions provide scientists with a sensitive all-in-one process to characterize so-called guide RNA (gRNA) -generated knockouts and knockouts. in small insertions when editing genes. The kit and solutions combine liquid sample preparation with downstream PCR detection as well as the Sanger method of DNA sequencing.
“These new, highly sensitive tools will dramatically reduce the time it takes to complete experiments, with cell culture requirements reduced by seven days compared to existing methods, thereby accelerating research in this cutting edge area,” said Thomas Schweins, vice-president. Senior President, Life Sciences. at QIAGEN. “They give new impetus to CRISPR’s potential for breakthroughs in biomedical research in cancer, neurological diseases, gene therapy, cell therapy, immunotherapy, regenerative medicine and disease modeling – and in discovery biomarkers of disease signaling and drug development. ”
The QIAprep & CRISPR Kit and CRISPR Q-Primer solutions are optimized for analyzes of cells edited with methods such as CRISPR with adherent and suspension cell cultures – including experiments with the Cas9 and Cas12a proteins often used to cleave the DNA – and can even be used with a single cell entry. Positive PCR controls for humans, mice and rats are included to determine the effectiveness of the gene editing conditions. Primers for PCR and Sanger sequencing can be easily customized to suit any target.
Unveiled less than a decade ago, CRISPR has revolutionized genomics by making genome editing in humans, plants and animals easy and inexpensive. CRISPR can locate a specific section of DNA inside a cell, then alter its function by altering its DNA sequence. It is widely used in scientific research, where it is hoped that it will transform drug development and even medicine as a whole.
Find more information on the QIAGEN CRISPR product offering: https://www.qiagen.com/yt/product-categories/discovery-and-translational-research/functional-and-cell-analysis/crispr/
QIAGEN NV, a Netherlands-based holding company, is the world’s leading provider of Sample to Insight solutions that enable customers to gain valuable molecular information from samples containing the building blocks of life. Our sampling technologies isolate and process DNA, RNA and proteins from blood, tissues and other materials. Assay technologies make these biomolecules visible and ready for analysis. Bioinformatics software and knowledge bases interpret data to yield relevant and actionable information. Automation solutions connect them in transparent and cost-effective workflows. QIAGEN provides solutions to more than 500,000 customers worldwide in the fields of molecular diagnostics (human health) and life sciences (universities, pharmaceutical R&D and industrial applications, mainly forensics). As of March 31, 2021, QIAGEN employed approximately 5,700 people at more than 35 locations around the world. Further information can be found at http://www.qiagen.com.
Certain statements contained in this press release may be considered as forward-looking statements within the meaning of Section 27A of the US Securities Act of 1933, as amended, and Section 21E of the US Securities Exchange Act of 1934, as amended. ‘fine. To the extent that any of the statements contained herein regarding QIAGEN’s products, including products used in the COVID-19 pandemic response, launch and development schedule, marketing approvals and / or regulatory, financial and operational outlook, growth and expansion, collaborative markets, strategy or operating results, including, without limitation, its adjusted net sales and its expected adjusted diluted results, are forward-looking, these statements are based on current expectations and assumptions which involve a number of uncertainties and risks. These uncertainties and risks include, but are not limited to, risks associated with managing growth and international operations (including the effects of currency fluctuations, regulatory processes and reliance on logistics), variability in results operations and allocations between customer categories; commercial development of markets for our products to academic, pharmaceutical, applied testing and molecular diagnostics customers; changing relationships with customers, suppliers and strategic partners; competition; rapid or unexpected technological changes; fluctuations in demand for QIAGEN’s products (including fluctuations due to general economic conditions, level and timing of customer financing, budgets and other factors); our ability to obtain regulatory approval for our products; difficulties in successfully adapting QIAGEN’s products to integrated solutions and producing such products; QIAGEN’s ability to identify and develop new products and to differentiate and protect our products from competitive products; market acceptance of new QIAGEN products and integration of acquired technologies and businesses; government actions, global or regional economic developments, weather or transport delays, natural disasters, political or public health crises, including the extent and duration of the COVID-19 pandemic and its impact on demand for our products and other aspects of our business, or other force majeure events; as well as the possibility that the expected benefits associated with recent or ongoing acquisitions will not materialize as expected; and other factors discussed under the heading âRisk Factorsâ in Item 3 of our most recent Annual Report on Form 20-F. For more information, please refer to the discussions in reports that QIAGEN has filed with or provided to the United States Securities and Exchange Commission.
Source: QIAGEN SA